Valuation: AP Biosciences, Inc.

Market Cap 13.36B 420M 369M 347M 317M 593M 40.27B 597M 4.17B 1.62B 20.53B 1.58B 1.54B 66.57B P/E 2024
-8.86x
P/E 2025 -34.4x
Enterprise Value 12.25B 385M 338M 318M 291M 543M 36.92B 547M 3.82B 1.48B 18.82B 1.45B 1.42B 61.03B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
52.82%
Yield 2024 *
-
Yield 2025 -
1 day+1.48%
1 week+14.17%
Current month+39.37%
1 month+34.98%
3 months+37.00%
6 months-24.31%
Current year-23.89%
1 week 114
Extreme 114
137.5
1 month 93
Extreme 93
137.5
Current year 86.1
Extreme 86.1
236
1 year 86.1
Extreme 86.1
236
3 years 36.3
Extreme 36.3
236
5 years 36.3
Extreme 36.3
236
10 years 36.3
Extreme 36.3
236
Manager TitleAgeSince
Chief Executive Officer - 26/05/2013
Director of Finance/CFO - 17/10/2022
Chief Administrative Officer - 17/10/2022
Director TitleAgeSince
Director/Board Member - 08/11/2022
Director/Board Member - 03/06/2019
Director/Board Member - 03/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%+14.17%+23.98%+137.44% 420M
+0.06%+6.49%+60.29%+111.13% 74.18B
+0.22%-3.57%+34.57%+75.40% 59.55B
-2.05%-3.46%-18.60%+352.20% 25.84B
-2.39%+2.74%+0.19%-5.91% 24.73B
-0.85%+1.29%+21.71%-9.84% 20.87B
+1.29%-2.49%+152.11%+333.06% 15.32B
-2.44%-0.09%+42.50%+164.11% 14.06B
-3.91%-4.91%-14.10%+779.68% 13.12B
-1.12%-3.04%+15.72%+234.56% 11.85B
Average -0.83%+0.69%+31.84%+217.18% 25.99B
Weighted average by Cap. -0.61%+0.72%+36.34%+161.43%

Financials

2024 2025
Net sales - -
Net income -423M -13.3M -11.67M -10.97M -10.03M -18.75M -1.27B -18.89M -132M -51.1M -650M -49.95M -48.85M -2.11B -445M -13.99M -12.28M -11.55M -10.56M -19.72M -1.34B -19.87M -139M -53.76M -683M -52.55M -51.4M -2.22B
Net Debt -1.47B -46.27M -40.61M -38.18M -34.9M -65.22M -4.43B -65.71M -459M -178M -2.26B -174M -170M -7.33B -1.11B -34.97M -30.69M -28.85M -26.38M -49.29M -3.35B -49.65M -347M -134M -1.71B -131M -128M -5.54B
Logo AP Biosciences, Inc.
AP Biosciences Inc is a Taiwan-based company mainly engaged in the research and development of protein drugs and antibody drugs. The Company develops early candidate drugs and preclinical trials, and develops different monoclonal or bispecific antibody drugs for potential targets, mechanisms of action, and disease characteristics through drug design and existing technology platforms. The Company's technology platform and bispecific protein drug research and development projects include IBI302-anti-vascular endothelial growth factor (VEGF) and anti-complement bifunctional recombinant protein, OmniMab fully human antibody library, AP505-PD-L1 x VEGF bispecific antibody, target-directed T cell activation 3T platform (T-cube), AP203-PD-L1 x CD137 fully human bispecific antibody, and others.
Employees
-
Date Price Change Volume
23/09/26 NT$137.00 +1.48% 476,937
22/09/26 NT$135.00 0.00% 626,964
21/09/26 NT$135.00 +2.27% 962,362
18/09/26 NT$132.00 +6.45% 1,216,424
17/09/26 NT$124.00 +3.33% 1,792,434
  1. Stock Market
  2. Stocks
  3. 6945 Stock